Understanding the role of ATP and P2X3 receptors in chronic cough
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients: an Exploratory Study
This study is trying to understand what causes chronic cough by looking at lung inflammation and a specific molecule in people with the cough compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 18 (estimated) |
| Ages | 30 Years to 70 Years |
| Sex | All |
| Sponsor | Imperial College London Academic / other |
| Locations | 2 sites (London and 1 other locations) |
| Trial ID | NCT06286163 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the underlying causes of chronic cough, defined as a cough lasting more than 8 weeks. Researchers will compare the lung inflammation and potential involvement of adenosine triphosphate (ATP) in patients with chronic cough to healthy individuals without the condition. The study will involve 10 participants suffering from chronic cough and 8 healthy controls to identify abnormalities associated with chronic cough. By examining these interactions, the research seeks to enhance understanding of this common yet poorly understood condition.
Who should consider this trial
Good fit: Ideal candidates include individuals with a chronic cough lasting at least 8 weeks and those who have been evaluated in a Cough Clinic.
Not a fit: Patients with significant respiratory diseases or those who have not been diagnosed with chronic cough may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and potentially new treatment options for patients suffering from chronic cough.
How similar studies have performed: While the approach is novel in its specific focus on ATP and P2X3 receptors, similar studies have explored chronic cough, but this particular interaction has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- 1. For Normal non-smoking subject: Healthy individuals, free of significant disease No history of asthma/rhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1/FVC ratio \>70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years 2\. For chronic cough participants: History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months. Undergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough. Would have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found. 3\. General Inclusion Criteria: Give written informed consent prior to participation in the study including all of its procedures. Comply with the requirements and restrictions listed in the consent form. Male or female subject aged between 30 and 70 years old at screening. Able to complete the study and all measurements. Able to read, comprehend, and write at a sufficient level to complete study related materials. Exclusion Criteria: \-
Where this trial is running
London and 1 other locations
- Royal Brompton & Harefield NHS Trust, — London, United Kingdom (Recruiting)
- Royal Brompton Hospital — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Kian Fan Chung, MD — Imperial College London
- Study coordinator: Kian Fan Chung, MD
- Email: f.chung@imperial.ac.uk
- Phone: 442075947959
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.